Let’s start nice and easy. What are the basics details for the new Speed Regime golf balls, and when can I try them? The golf ball R&D team has cooked up some beauties for 2014. Speed Regime is a new series of tour golf balls from Callaway Golf. There are three unique golf balls: SR […]
Agreement secures full Elekta solution across the McLaren enterprise STOCKHOLM, December 18, 2013 – The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care […]
— High Cure Rates Observed with Single Tablet Regimen May Eliminate Interferon and Ribavirin from HCV Therapy for Genotype 1 Patients — — U.S. NDA Submission Planned for Q1 2014– FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 18, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from three Phase 3 clinical trials (ION-1, ION-2 and ION-3) evaluating the […]
TARRYTOWN, N.Y., Dec. 18, 2013 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA […]
Menlo Park, California and INGELHEIM, Germany, 18 December, 2013 – Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. […]
PITTSBURGH, Dec. 18, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready to […]
Families with infants in the Hemby Neonatal Intensive Care Unit will have a private place of respite December 17, 2013 – A ribbon cutting ceremony was held on Dec. 10 to celebrate the grand opening of Tucker’s Room – the newly renovated waiting room for families with infants in the Novant Health Hemby Neonatal Intensive […]
Captures Five Optical Measurements in One High-Resolution Scan; Same Wavefront Sensing Technology Used to Measure NASA’s James Webb Space Telescope’s Optics December 17, 2013 — Abbott Park, Illinois (NYSE: ABT) — With the introduction of Abbott’s iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second […]
– Biogen Idec Opts-In to Commercialization Opportunity with Joint Venture Partner – CAMBRIDGE, Mass. & SEOUL, Korea–(December 17, 2013)–Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to […]
Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will […]